



OPEN

In vivo magnetic resonance spectroscopy by transverse relaxation encoding with narrowband decoupling

Li An^{1,2}✉ & Jun Shen¹

Cell pathology in neuropsychiatric disorders has mainly been accessible by analyzing postmortem tissue samples. Although molecular transverse relaxation informs local cellular microenvironment via molecule-environment interactions, precise determination of the transverse relaxation times of molecules with scalar couplings (J), such as glutamate and glutamine, has been difficult using in vivo magnetic resonance spectroscopy (MRS) technologies, whose approach to measuring transverse relaxation has not changed for decades. We introduce an in vivo MRS technique that utilizes frequency-selective editing pulses to achieve homonuclear decoupled chemical shift encoding in each column of the acquired two-dimensional dataset, freeing up the entire row dimension for transverse relaxation encoding with J-refocusing. This results in increased spectral resolution, minimized background signals, and markedly broadened dynamic range for transverse relaxation encoding. The in vivo within-subject coefficients of variation for the transverse relaxation times of glutamate and glutamine, measured using the proposed method in the human brain at 7 T, were found to be approximately 4%. Since glutamate predominantly resides in glutamatergic neurons and glutamine in glia in the brain, this noninvasive technique provides a way to probe cellular pathophysiology in neuropsychiatric disorders for characterizing disease progression and monitoring treatment response in a cell type-specific manner in vivo.

Magnetic resonance spectroscopy (MRS) enables noninvasive detection of molecules in vivo, including those found in the highly inaccessible human brain. Neuropsychiatric disorders and brain tumors are among the most active areas of in vivo MRS research. Accurate in vivo detection of key neurochemicals such as glutamate (Glu), glutamine (Gln), and glutathione (GSH) is highly important in these fields. Glu is the primary excitatory neurotransmitter in the central nervous system (CNS). The metabolic coupling between Glu and Gln forms the Glu-Gln neurotransmitter cycle between glutamatergic neurons and glia^{1,2}. Glu and Gln are also major metabolites in the CNS, playing crucial roles in normal brain function and cancer cell growth^{3,4}. GSH is an antioxidant, whose level is a marker of redox state⁵. Glu, Gln, and GSH have been implicated in many illnesses such as epilepsy, schizophrenia, bipolar disorders, Alzheimer's disease, major depressive disorder, anxiety disorders, and brain tumors^{6–11}. Many brain disorders are also associated with alterations in cell type-specific microenvironments¹², which are difficult to measure noninvasively. For instance, postmortem studies have found ample evidence of glial pathology in major depressive disorder^{13,14} and one of the defining characteristics of the pathophysiological state of Alzheimer's disease is the atrophy of glutamatergic neurons¹⁵.

For the majority of in vivo single-voxel MRS experiments, localized one-dimensional free induction decay (FID) signals are acquired with a large number of transients to achieve sufficient signal-to-noise ratio (SNR). Chemical shift information is frequency-encoded in the FIDs, along with signal modulation due to J-coupling. The frequency domain MRS spectrum is obtained by Fourier transforming the sum of all transients. Signal modulation due to J-coupling causes peak splitting in an MRS spectrum, which can impair quantification by reducing peak amplitudes and increasing spectral overlap among different molecules and with the background signals (macromolecule signals and the background spectral baseline). Recent MRS studies of the human brain have revealed errors and uncertainties in modeling background signals in the widely used short echo time (TE) spectra^{16–19}.

¹Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. ²Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room 3D46, 10 Center Drive, MSC 1216, Bethesda, MD 20892-1216, USA. ✉email: li.an@nih.gov

In addition to measuring concentrations, *in vivo* MRS can also determine transverse relaxation times (T_2)^{20–24}. Unlike the T_2 of tissue water measured by magnetic resonance imaging (MRI), the molecular T_2 s measured by MRS are often cell type-specific and can provide critical information on the cellular microenvironment where the molecules reside through molecule-local environment interactions^{25–29}. For instance, in the brain, Glu and Gln are predominantly localized in glutamatergic neurons and glia, respectively. Reliable detection of Glu and Gln T_2 s can therefore provide unique information on the microenvironments of these different cell types *in vivo*.

There are several inherent difficulties in reliably measuring T_2 of J-coupled molecules: (i) the signal intensity of many J-coupled molecules is low, partly due to peak splitting caused by J-couplings; (ii) due to J-evolution and spectral overlap, the optimal TE for reliable detection of a J-coupled molecule is fixed^{23,30,31}, while T_2 measurements require a series of very different time points for transverse relaxation encoding; (iii) the background signals also change with TE³², and the uncertainty and errors in modeling the background signals lead to significant errors in T_2 measurements.

Compared to one-dimensional (1D) MRS, two-dimensional (2D) MRS techniques^{33–37} offer many unique capabilities. For example, effective homonuclear decoupling can be achieved in the context of 2D MRS to significantly improve spectral resolution *in vivo*^{34,38–42}. Among them, the 2D ProFit technique has been used to estimate neurochemical T_2 s^{43–45}.

In this work, we introduce a novel 2D MRS technique, Transverse Relaxation Encoding with Narrowband Decoupling (TREND), for *in vivo* measurement of neurochemical concentrations and T_2 relaxation times. By using frequency-selective editing pulses, this technique achieves chemical shift encoding with selective homonuclear decoupling in the column (t_1) dimension and T_2 encoding with single or double J-refocusing in the row (t_2) dimension. This technique addresses the difficulties in measuring the concentrations and T_2 s of J-coupled molecules by: (i) selectively decoupling the targeted spins in the column dimension; (ii) allowing T_2 encoding at many time points with markedly broadened dynamic range; (iii) utilizing relatively long TEs and, to a lesser extent, the TE averaging effect^{46,47} to minimize the background signals. As an application of this technique, the concentrations and T_2 relaxation times of Glu, Gln, and GSH—three important biomarkers for neuropsychiatric and brain cancer research—are measured in the human brain *in vivo*.

Results

Density matrix simulated^{48,49} bin spectra of lactate (Lac) and Gln are shown in Fig. 1. For each molecule, two sets of bin spectra were calculated with the frequency-selective editing pulses switched off and on, respectively. Since there is no reported T_2 value for Lac in the healthy human brain, the T_2 of Lac was set to 180 ms, similar to that of Glu in the grey matter²³. T_2 of Gln was set to 80 ms²³. All bin spectra were line broadened to a typical *in vivo* linewidth of 9 Hz. Without the editing pulses (Fig. 1A), the Lac peak is a doublet with low amplitude for bin 0 and becomes even lower for bins 1–3 due to its H2–H3 J-evolution. In contrast, when the editing pulses are turned on (Fig. 1B), the frequency band at 4.10 ppm locks the H2–H3 J-evolution in the column (t_1) dimension. As a result, the Lac H3 peak becomes a sharp singlet in the column dimension with much higher amplitude in all four bin spectra. Gln has a more complex spin system with a strong internal coupling between its two H4 protons but weak external couplings between its H3 and H4 protons⁵⁰. Without the editing pulses, the Gln H4 signal is greatly diminished due to J-evolution and signal self-cancellation (Fig. 1C). By applying the editing pulses to the H3 resonances of Gln at 2.12 ppm, the H3–H4 J-evolutions are locked in the column dimension, resulting in a sharp pseudo singlet for the H4 signal with significantly higher peak intensity (Fig. 1D). Figure 1 shows that the application of the editing pulses resulted in a significant improvement in both spectral resolution and peak amplitude for the targeted spins.

Density matrix simulated bin spectra of N-acetylaspartate (NAA) using single-band (A) and dual-band (B) editing pulses are shown in Fig. 2. T_2 was set to 200 ms for acetyl CH₃ and 140 ms for aspartyl CH₂²³. All bin spectra were line broadened to a typical *in vivo* linewidth of 9 Hz. In Fig. 2A, the NAA aspartyl CH₂ resonances at 2.4–2.6 ppm are relatively large and interfere with the detection of Glu and GSH. In contrast, in Fig. 2B, these resonances were effectively suppressed in bins 0–3 due to the second band targeting 4.38 ppm.

The proposed technique was used to measure the concentrations and T_2 s of Glu, Gln, GSH, total creatine at 3.03 ppm (tCr), and total choline at 3.21 ppm (tCho) in the human brain. Figure 3 shows the first four bin spectra acquired from a healthy participant and the re-test results are provided in the Supplementary Information. The Gln H4 signal appears as a sharp pseudo singlet in the bin spectra, which is consistent with the numerical simulation shown in Fig. 1D. The Gln peak remains detectable in bin 3, which has an average TE (TE_{bin}) of 220.4 ms. Figure 4 displays the spectra for all 11 bins and their corresponding fitted spectra. The fitted spectra in the fitting range (1.8–3.4 ppm) closely resemble the *in vivo* spectra for all 11 bins. The Glu peak appears prominent in bins 0–3, which span 71.4–220.4 ms, and is still detectable in bin 10, which has a very long TE_{bin} of 458.4 ms. Figure 5 shows the fitting details for bins 0, 1, and 8. The model spectra fit the *in vivo* spectra well, as evidenced by the small residuals.

Linear regressions of $\ln(\text{conc}_{bin})$ on TE_{bin} for tCr, tCho, Glu, Gln, and GSH are shown in Fig. 6. NAA was not analyzed as it was partially dephased by the 2.12 ppm band of the editing pulses and the crusher gradients. The T_2 -weighted concentrations (conc_{bin}) were obtained by fitting the bin spectra shown in Fig. 4. The single exponential model was found to fit the *in vivo* T_2 decay data well. The coefficients of determination (R^2) were greater than 0.95 for tCr, tCho, Glu, and Gln (see Table 1). Table 1 lists the neurochemical concentrations, as ratios to [tCr], and T_2 relaxation times obtained from the linear regressions.

The voxel had 54.5% ± 5.1% grey matter, 37.9% ± 5.0% white matter, and 7.6% ± 4.4% cerebrospinal fluid. The within-subject coefficients of variation (CVs) were calculated from test and re-test measurements of the same voxel.




Figure 1. Numerically calculated bin spectra of Lac (A,B) and Gln (C,D). The pulse sequence used is shown in Fig. 8 in the “Methods” section. Each stack plot displays a subset of the 11 bin spectra obtained. The dual-band editing pulses (denoted as 180_s) had two 180° bands, one at 2.12 ppm and the other at 4.10 ppm. The editing pulses were turned off in (A) and (C) and on in (B) and (D). The [Lac]:[Gln] ratio was 1:7. TE_{bin} represents the average TE of each bin. *Lac* lactate, *Gln* glutamine.

Discussion

Cellular pathology in brain disorders has mainly been characterized by postmortem methods^{12–15}, which are difficult to standardize due to uncontrollable physicochemical and morphological changes in cells after death, complicating the understanding of disease etiology and development of effective treatment strategies. For example, although numerous postmortem studies have implicated glutamatergic dysregulation in central pathologies, progress in developing therapeutics targeting the glutamatergic system has been relatively slow. This is due, in part, to the lack of tools that can probe and monitor the pathophysiological processes in glutamatergic neurons and glia accompanying disease progression and treatment response.

MRS has high potential for generating cell type-specific contrast in vivo via molecule-environment interactions. However, the precision of measuring T_2 of J-coupled molecules using previously published MRS technologies has been inadequate. Furthermore, recent methodological re-examination of short-TE MRS for neurochemical profiling has found that spectral overlap between neurochemicals and the background signals, as well as between neurochemicals, can result in significant errors in both quantifying neurochemical concentrations and determining correlations between neurochemical concentrations and clinical metrics^{16,17,51,52}. These errors propagate into T_2 measurements that include short-TE spectra. Although neurochemical concentrations measured by spectral fitting of short-TE MRS spectra have been treated implicitly or explicitly as spectrally uncorrelated variables in clinical MRS studies, severe spectral overlap can confound determination of correlations of biological origin⁵².

Alternatively, some 1D in vivo MRS experiments use relatively long TE to minimize the problematic background signals. However, this approach suffers from unknown T_2 weighting, as changes in T_2 are associated with many diseases^{26,27,29}. Different T_2 weightings are routinely encountered in clinical MRS literature, leading to many controversies in clinical MRS findings²⁷. When the previously published MRS techniques are used to measure molecular T_2 s, the dynamic range for encoding the T_2 s of J-coupled molecules can be very limited. This is because it is necessary to detect J-coupled molecules at fixed TEs for optimal sensitivity and spectral resolution due to J-evolution and spectral overlap^{23,30}. In the literature, the Glu peak was detectable up to a TE of 374 ms⁵³, while the Gln peak was detectable up to a TE of 130 ms²³. Moreover, to the best of our knowledge, the precision of T_2 measurements, in terms of CRLBs or within-subject CVs, has not been reported.

By utilizing frequency-selective pulses, the proposed technique achieves chemical shift encoding with homonuclear decoupling of the targeted spins in the column (t_1) dimension and J-refocusing of the targeted spins in the row (t_2) dimension. The J-evolutions of the targeted spins are refocused at $TE = 70$ ms by the first editing pulse




Figure 2. Numerically calculated bin spectra of NAA obtained using single-band (A) and dual-band (B) editing pulses. The single-band 180° editing pulses were applied at 2.12 ppm. The dual-band editing pulses had a 180° band at 2.12 ppm and a 90° band at 4.38 ppm targeting the NAA aspartyl CH proton. The remaining parameters are provided in Fig. 8 in the “Methods” section. The pair of dashed lines in each stack plot indicate the 2.4–2.6 ppm range, where Gln and GSH glutamyl H4 protons resonate. NAA N-acetylaspartate.

and refocused again at TE = 157.6 ms by the second editing pulse while undergoing T_2 decay in the row dimension and maintaining high-amplitude pseudo-singlet spectral structure in the column dimension. Consequently, the dynamic range for measuring the T_2 s of the targeted J-coupled spins is greatly expanded. Although the dataset is acquired in a 2D fashion, no coherence or polarization transfer occurs in the experiment by design. Therefore, a 2D Fourier transform of the acquired dataset is not used. Instead, Fourier transforms are only applied in the column (t_1) dimension. In the row (t_2) dimension, all columns are averaged into a small number of bins to increase the SNR of each spectrum and speed up the post-processing procedure for calculating the neurochemical T_2 s. This technique enables the detection of Glu and Gln up to unprecedented long TEs of 458 ms (bin 10) and 220 ms (bin 3), respectively. The very high precision of Glu and Gln T_2 s, as shown in Table 1, makes this technique a viable method for characterizing cellular pathophysiology of glutamatergic neurons and glia in vivo.

For all six healthy participants, the specific absorption rate (SAR) was below 60% of the limit, indicating that the SAR limit does not pose a problem for this sequence at 7 T. As described in the Supplementary Information, the bandwidth of the refocusing pulses is 2.0 kHz. The maximum chemical shift displacement for the neurochemicals of interest, which are the closely resonating Glu, Gln, and GSH glutamyl H4 protons, is only $\pm 1.7\%$ of the voxel size. Additionally, it is possible to use adiabatic slice-selective pulses in the pulse sequence to further reduce the chemical shift displacement error.

Since the current sequence of the proposed technique is designed to measure the concentrations and T_2 s of Glu, Gln, and GSH, a parsimonious fitting range of 1.8–3.4 ppm is sufficient for reliable quantification of these neurochemicals. The NAA singlet at 2.01 ppm is only 33 Hz away from the 2.12 ppm band of the editing pulses, causing partial dephasing of the NAA singlet. Therefore, NAA was not included in the analysis. Similar to other spectral editing techniques, B_1 inhomogeneity can introduce quantification errors in this technique. However, this B_1 inhomogeneity issue may be mitigated by using parallel RF transmission (pTx). Neurochemical quantification using this technique is expected to be less affected by line broadening caused by B_0 inhomogeneity since the targeted J-coupled peaks are pseudo singlets, which are better resolved than multiplets, as shown in Figs. 3, 4 and 5. The shortest TE in our spectra is 71.4 ms for bin 0, which may limit the ability of our method to detect much shorter neurochemical T_2 s. The current implementation of this technique also has a relatively long scan time, which could be reduced in future studies. The high quality of the spectra obtained in this study indicates that the voxel size can also be reduced in future investigations. Adapting this technique to a spectroscopic imaging technique would require an echo planar imaging (EPI) or a similar readout. Furthermore, utilizing this




Figure 3. In vivo bin spectra (0–3) acquired from a $2 \times 3.5 \times 2$ cm³ voxel in the cingulate cortex of a healthy participant. The pulse sequence used to acquire the in vivo data was the same as that used for Fig. 2B, employing dual-band editing pulses to simultaneously lock the H3–H4 couplings and suppress the NAA aspartyl resonances between 2.4 and 2.6 ppm. No line broadening was applied to the spectra. TE_{bin} represents the average TE of each bin. *mI* myo-Inositol, *tCho* total choline, *tCr* total creatine. The full dataset is shown in Fig. 4.

technique at lower magnetic field strengths, such as at 3 T, for detecting Glu, Gln, and GSH T₂ values is expected to be challenging due to reduced chemical shift dispersion.

Another limitation of the proposed technique is the potential diffusion effect on the measured neurochemical T₂ values. A rigorous assessment of T₂ in liquids requires the use of many closely spaced 180° refocusing pulses to minimize the diffusion effect. However, this inevitably generates the T₁ effect in spatially localized MRS, as the magnetization spends a significant amount of time outside of the transverse plane during the execution of the many long selective refocusing pulses. It should be noted that, for the practical purpose of using Glu and Gln as endogenous cell type-specific markers or contrast agents, excluding diffusion effect may not be necessary or even desirable. This is because neurochemical diffusion abnormality per se may contribute to the differentiation of cellular pathology.

In summary, we have developed a novel MRS technique that overcomes the inherent difficulties in measuring T₂ of J-coupled neurochemicals in vivo. It achieves chemical shift encoding with frequency-selective decoupling in each column of the acquired 2D dataset. Chemical shift and T₂ are separately encoded in different dimensions. The columns of the 2D dataset are averaged into a small number of bins with the J-splitting of the targeted spins fully eliminated or suppressed. The background signals in the bin spectra are minimized by T₂ decay and TE averaging. The dynamic range for measuring the T₂s of the targeted spins is markedly broadened to 458 ms for Glu and 220 ms for Gln due to the decoupling effect of the editing pulses in the column (t₁) dimension and the J-refocusing effect of the editing pulses in the row (t₂) dimension. Furthermore, multi-band editing pulses can be used to decouple multiple molecules and suppress unwanted interfering signals.

As an application of the proposed technique, the concentrations and T₂ relaxation times of Glu, Gln, and GSH were measured. Bin spectra with well-resolved and sharp Glu, Gln, and GSH peaks were obtained with minimized spectral interference from the NAA aspartyl signals at 2.4–2.6 ppm. Glu and Gln T₂s were quantified



Figure 4. In vivo bin spectra (0–10) and their fits. The entire scan time was 10 min and 43 s using a 2.5 s repetition time (TR).




Figure 5. Examples of fitting details for the bin spectra displayed in Fig. 4.

with very high precision. The proposed technique therefore offers a viable approach for noninvasively establishing cell type-specific biomarkers of cellular pathophysiology in neuropsychiatric disorders in vivo.

Methods

Proof of concept. A schematic diagram of a basic pulse sequence for the proposed technique is shown in Fig. 7A. This sequence is created by adding a 180° frequency-selective editing pulse at the midpoint between the two 180° refocusing pulses of a point-resolved spectroscopy (PRESS) sequence⁵⁴. The editing pulse has a dura-




Figure 6. Linear regression of $\ln(\text{conc}_{\text{bin}})$ on TE_{bin} . The T_2 -weighted concentrations (conc_{bin}) were obtained by fitting the bin spectra shown in Fig. 4.

	Neurochemical ratio ($1/[\text{tCr}]$)	CRLB (%)	CV (%)	T_2 (ms)	CRLB (%)	CV (%)	R^2
tCr $[\text{N}(\text{CH}_3)]$	1	1.1 ± 0.3	0	116 ± 6	0.6 ± 0.1	2.3	0.99 ± 0.00
tCho $[\text{N}(\text{CH}_3)_3]$	0.21 ± 0.01	1.2 ± 0.3	2.4	182 ± 12	0.8 ± 0.2	2.7	0.99 ± 0.01
Glu	1.38 ± 0.12	2.1 ± 0.6	5.6	142 ± 11	1.8 ± 0.5	3.9	0.97 ± 0.03
Gln	0.52 ± 0.09	9.3 ± 2.4	7.1	77 ± 8	6.1 ± 1.9	4.0	0.95 ± 0.06
GSH	0.24 ± 0.07	20.8 ± 16.1	16.2	98 ± 17	15.1 ± 11.1	9.6	0.82 ± 0.19

Table 1. Quantification of neurochemical concentrations ($1/[\text{tCr}]$) and T_2 relaxation times in the cingulate cortex of healthy participants ($n = 6$; mean \pm SD).

tion of 15 ms and its amplitude profile is generated by truncating a Gaussian function at one standard deviation on each side, leading to a full width half maximum (FWHM) bandwidth of 73 Hz. This editing pulse is applied at 4.10 ppm, targeting the H2 methine proton of lactate, to achieve homonuclear decoupled chemical shift encoding for the H3 protons of lactate at 1.31 ppm. The timing parameters τ_1 , τ_2 , and τ_3 are labeled in Fig. 7A and their values are: $\tau_1 = 17.5$ ms, $\tau_3 = 8.3$ ms, and $\tau_2 = \tau_{2,0} + m\Delta\tau_2$, where $\tau_{2,0} = 17.5$ ms, m is the τ_2 increment number given by $m = 0, 1, \dots, 255$, and $\Delta\tau_2 = 0.4$ ms. The data acquisition window ADC_1 uses a dwell time of 0.2 ms and acquires 1060 data points. The pulse sequence uses 256 τ_2 increments with fixed τ_1 and τ_3 .

A 256×1060 2D dataset was simulated for 256 τ_2 increments using the pulse sequence shown in Fig. 7A. A schematic diagram of the timing of the data points is shown in Fig. 7B. The row number m and column number n are labeled using zero-based numbering. The chemical shift encoding time $t_{\text{CSE}}(m, n)$ for data point (m, n) , which is the time delay between the echo center at $4\tau_2$ and the n th data point at $\tau_1 + 2\tau_2 + \tau_3 + n\Delta t$ for the m th τ_2 increment, is given by:

$$t_{\text{CSE}}(m, n) = \tau_1 + \tau_3 - 2\tau_{2,0} + n\Delta t - 2m\Delta\tau_2. \quad (1)$$

This shows that the column-wise time interval is $2\Delta\tau_2$ (0.8 ms), which is equal to $4\Delta t$.

For efficient data processing, the column-wise resolution is increased by a factor of 4 using sinc interpolation. After sinc interpolation, the dataset size in the (m', n) space becomes 1024×1060 and the time intervals in both dimensions are Δt , as shown in Fig. 7C. The chemical shift encoding time $t_{\text{CSE}}(m', n)$ is the time delay between the echo center at $4\tau_2$ and the n th data point at $\tau_1 + 2\tau_2 + \tau_3 + n\Delta t$ in the m' th row of the sinc-interpolated dataset. It is given by:

$$t_{\text{CSE}}(m', n) = (n - m' - n_0)\Delta t, \quad (2)$$

where $n_0 = (2\tau_{2,0} - \tau_1 - \tau_3)/\Delta t = 46$. By setting $t_{\text{CSE}}(m', n)$ to zero, the equation for echo centers is $n - m' - n_0 = 0$, forming the 45° diagonal line shown in Fig. 7C. The row number for the echo center in the n th column is given by:

$$m'_{\text{ec}}(n) = n - n_0. \quad (3)$$

The TE value for the echo center in the n th column, which is the time delay between the excitation pulse and the echo center in row $m'_{\text{ec}}(n)$, is given by:




Figure 7. Basic pulse sequence and 2D datasets of the proposed TREND technique. **(A)** Schematic diagram of the basic pulse sequence. The frequency-selective editing pulse is denoted as 180_s . $\tau_1 = 17.5$ ms; $\tau_2 = \tau_{2,0} + m\Delta\tau_2$, where $\tau_{2,0} = 17.5$ ms, $m = 0, 1, \dots, 255$, and $\Delta\tau_2 = 0.4$ ms; $\tau_3 = 8.3$ ms; duration of $180_s = 15$ ms; dwell time $\Delta t = 0.2$ ms. **(B)** The 2D dataset in the (m, n) space. **(C)** The 2D dataset in the (m', n) space after sinc-interpolation. **(D)** The 2D dataset in the (m'', n) space after aligning the echo centers.

$$TE(n) = 2\tau_1 + 2\tau_3 + 2n\Delta t. \quad (4)$$

Each column in the (m', n) space is then shifted upwards by $m'_{ec}(n)$ data points such that the echo centers of all columns lie on the horizontal n -axis. This creates a new dataset in the (m'', n) space, where the new row number m'' has both positive and negative values, with the positive direction being upward (see Fig. 7D). Note that the positive m'' direction in Fig. 7D corresponds to the negative m' direction in Fig. 7C. The void data points in Fig. 7D are filled with zeros. In the (m'', n) space, the chemical shift encoding time for data point (m'', n) becomes independent of the column number n and is given by:

$$t_{CSE}(m'') = m''\Delta t. \quad (5)$$

This shows that the chemical shift information is Fourier-encoded in each column.

Due to the frequency-selective 180° pulse at $\tau_1 + \tau_2$ targeting spin S of the lactate I_3S spin system, the J-evolution of spin I is fully refocused at $2\tau_1 + 2\tau_2$, which is $\tau_1 - \tau_3$ after the start of data acquisition for all τ_2 increments. The column number for the data points with fully refocused J-evolution is $n_{JR} = (\tau_1 - \tau_3)/\Delta t = 46$. Using the product operator formalism^{55–57}, the J-modulation factor of spin I at data point (m, n) is:

$$f_{JM}(n) = \cos[\pi J(n - n_{JR})\Delta t], \quad (6)$$

indicating a constant J-modulation factor in each column and therefore achieving homonuclear decoupling of the targeted spins in the column dimension.




Figure 8. Schematic diagram of the TREND pulse sequence with a second editing pulse (180_s), a second ADC (ADC_2), and a STEAM block for acquiring unsuppressed water signals. The time delay between the main sequence block and the STEAM block is $2\tau_{2,last} - 2\tau_2$, where $\tau_{2,last}$ is the τ_2 value for the last τ_2 increment. $\tau_1 = 17.5$ ms; $\tau_2 = \tau_{2,0} + m\Delta\tau_2$, where $\tau_{2,0} = 17.5$ ms, $m = 0, 1, \dots, 255$, and $\Delta\tau_2 = 0.4$ ms; $\tau_3 = 8.3$ ms; $\tau_4 = 21.9$ ms; $\tau_5 = 10.9$ ms; duration of $180_s = 15$ ms; $ADC_1/ADC_2/ADC_3$ data points = 100/850/512; and $\Delta t = 0.2$ ms.

To improve the SNR and data processing efficiency, the columns of a dataset were averaged into a small number of bins. Each bin spectrum contains a frequency dependent Bloch-Siegert phase shift function⁵⁸ due to the frequency-selective editing pulse. The Bloch-Siegert phase shift function is the same for both row and column dimensions. As a result, the Bloch-Siegert phase shift function for the bin spectra was calculated by density matrix simulation at a single τ_2 value.

The second editing pulse. As depicted in Fig. 8, a second frequency-selective editing pulse is added to the basic pulse sequence in Fig. 7A. Implementation details of this pulse sequence are provided in the Supplementary Information. The number of data points for ADC_1 is reduced to 100 and the number of data points for ADC_2 is set to 850. The values for τ_1 , τ_2 , and τ_3 values remain the same as in Fig. 7A. The neurochemical signals acquired by ADC_1 and ADC_2 are combined and placed into a single 2D dataset in the (m, n) space. The time delay between the start of ADC_1 and the start of ADC_2 is $\tau_1 + \tau_4 + \tau_5 - \tau_3 = 110\Delta t$. Overall, the 2D dataset contains 256 rows and 1060 ($100 + 110 + 850$) columns, in which columns 100–209 are filled with zeros. J-evolution for the targeted spins in column 265 ($210 + (\tau_4 - \tau_5)/\Delta t$) is refocused by the 2nd editing pulse.

A stimulated echo acquisition mode (STEAM)⁵⁹ block is appended to the main sequence block to acquire unsuppressed water signals for computing sensitivities of the multi-channel receiver coil⁶⁰ and frequency correction⁴⁹. This STEAM block also pre-saturates the longitudinal magnetizations for the next τ_2 increment.

In vivo experiments. Six healthy participants (4 female and 2 male; age = 44 ± 13 years) were recruited and scanned using a Siemens Magnetom 7 T scanner. Written informed consent was obtained from the participants before the study following the procedures approved by the Institutional Review Board (IRB) of the National Institute of Mental Health (NIMH; NCT01266577). All experimental protocols and methods were performed in accordance with the guidelines and regulations of NIH MRI Research Facility. A three-dimensional (3D) T_1 -weighted magnetization prepared rapid gradient echo (MPRAGE) image was acquired with $TR = 3$ s, $TE = 3.9$ ms, data matrix = $256 \times 256 \times 256$, and spatial resolution = $1 \times 1 \times 1$ mm³. A $2 \times 3.5 \times 2$ cm³ MRS voxel was placed in the cingulate cortex with a water linewidth of 13.4 ± 1.6 Hz. The proposed pulse sequence (Fig. 8) was used to acquire data with dual-band editing pulses. These pulses had a 180° band at 2.12 ppm and a 90° band at 4.38 ppm targeting the NAA aspartyl CH proton. Seven variable power RF pulses (sinc-Gauss pulse; duration = 26 ms; FWHM bandwidth = 105 Hz) with optimized relaxation delays (VAPOR) were used for water suppression.

The in vivo dataset in the (m', n) space was averaged into 11 bins with bin 0 containing all 100 columns of data from ADC_1 and the remaining 850 columns from ADC_2 evenly divided by bins 1–10. Details on T_2 quantification are provided in the Supplementary Information.

Data availability

The data acquired during the study and the code developed to analyze the acquired data are available at [https://www.nitrc.org/doi/landing_page.php? https://doi.org/10.25790/bml0cm.134](https://www.nitrc.org/doi/landing_page.php?https://doi.org/10.25790/bml0cm.134).

Received: 7 April 2023; Accepted: 25 July 2023

Published online: 27 July 2023

References

- Sibson, N. R. *et al.* In vivo ^{13}C NMR measurements of cerebral glutamine synthesis as evidence for glutamate–glutamine cycling. *Proc. Natl. Acad. Sci. U. S. A.* **94**, 2699–2704. <https://doi.org/10.1073/pnas.94.6.2699> (1997).
- Shen, J. *et al.* Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo ^{13}C NMR. *Proc. Natl. Acad. Sci. U. S. A.* **96**, 8235–8240. <https://doi.org/10.1073/pnas.96.14.8235> (1999).
- Yi, H., Talmon, G. & Wang, J. Glutamate in cancers: From metabolism to signaling. *J. Biomed. Res.* **34**, 260–270. <https://doi.org/10.7555/JBR.34.20190037> (2019).
- Cluntun, A. A., Lukey, M. J., Cerione, R. A. & Locasale, J. W. Glutamine metabolism in cancer: Understanding the heterogeneity. *Trends Cancer* **3**, 169–180. <https://doi.org/10.1016/j.trecan.2017.01.005> (2017).
- Dringen, R., Brandmann, M., Hohnholt, M. C. & Blumrich, E. M. Glutathione-dependent detoxification processes in astrocytes. *Neurochem. Res.* **40**, 2570–2582. <https://doi.org/10.1007/s11064-014-1481-1> (2015).
- Ramadan, S., Lin, A. & Stanwell, P. Glutamate and glutamine: A review of in vivo MRS in the human brain. *NMR Biomed.* **26**, 1630–1646. <https://doi.org/10.1002/nbm.3045> (2013).
- Fazzari, J., Lin, H., Murphy, C., Ungard, R. & Singh, G. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. *Sci. Rep.* **5**, 8380. <https://doi.org/10.1038/srep08380> (2015).
- Das, T. K. *et al.* Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. *Prog. Neuro-Psychopharmacol.* **91**, 94–102. <https://doi.org/10.1016/j.pnpb.2018.08.006> (2019).
- Ekici, S., Risk, B. B., Neill, S. G., Shu, H. K. & Fleischer, C. C. Characterization of dysregulated glutamine metabolism in human glioma tissue with (^1H) NMR. *Sci. Rep.* **10**, 20435. <https://doi.org/10.1038/s41598-020-76982-7> (2020).
- Kennedy, L., Sandhu, J. K., Harper, M. E. & Cuperlovic-Culf, M. Role of glutathione in cancer: From mechanisms to therapies. *Biomolecules* <https://doi.org/10.3390/biom10101429> (2020).
- Ekici, S. *et al.* Glutamine imaging: A new avenue for Glioma management. *AJNR Am. J. Neuroradiol.* **43**, 11–18. <https://doi.org/10.3174/ajnr.A7333> (2022).
- Miladinovic, T., Nashed, M. G. & Singh, G. Overview of glutamatergic dysregulation in central pathologies. *Biomolecules* **5**, 3112–3141. <https://doi.org/10.3390/biom5043112> (2015).
- Rajkowska, G. & Miguel-Hidalgo, J. J. Gliogenesis and glial pathology in depression. *CNS Neurol. Disord. Drug Targets* **6**, 219–233. <https://doi.org/10.2174/187152707780619326> (2007).
- Czeh, B. & Nagy, S. A. Clinical findings documenting cellular and molecular abnormalities of glia in depressive disorders. *Front. Mol. Neurosci.* **11**, 56. <https://doi.org/10.3389/fnmol.2018.00056> (2018).
- Kocahan, S. & Dogan, Z. Mechanisms of Alzheimer's disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, Tau protein and other risk factors. *Clin. Psychopharmacol. Neurosci.* **15**, 1–8. <https://doi.org/10.9758/cpn.2017.15.1.1> (2017).
- Giapitzakis, I. A., Borbath, T., Murali-Manohar, S., Avdievich, N. & Henning, A. Investigation of the influence of macromolecules and spline baseline in the fitting model of human brain spectra at 9.4T. *Magn. Reson. Med.* **81**, 746–758. <https://doi.org/10.1002/mrm.27467> (2019).
- Zhang, Y. & Shen, J. Effects of noise and linewidth on in vivo analysis of glutamate at 3 T. *J. Magn. Reson.* **314**, 106732. <https://doi.org/10.1016/j.jmr.2020.106732> (2020).
- Marjanska, M. & Terpstra, M. Influence of fitting approaches in LCMoDel on MRS quantification focusing on age-specific macromolecules and the spline baseline. *NMR Biomed.* **34**, e4197. <https://doi.org/10.1002/nbm.4197> (2021).
- Simicic, D. *et al.* In vivo macromolecule signals in rat brain (^1H) -MRS spectra at 9.4T: Parametrization, spline baseline estimation, and T(2) relaxation times. *Magn. Reson. Med.* **86**, 2384–2401. <https://doi.org/10.1002/mrm.28910> (2021).
- Kreis, R., Slotboom, J., Hofmann, L. & Boesch, C. Integrated data acquisition and processing to determine metabolite contents, relaxation times, and macromolecule baseline in single examinations of individual subjects. *Magn. Reson. Med.* **54**, 761–768. <https://doi.org/10.1002/mrm.20673> (2005).
- Marjanska, M. *et al.* Localized ^1H NMR spectroscopy in different regions of human brain in vivo at 7 T: T2 relaxation times and concentrations of cerebral metabolites. *NMR Biomed.* **25**, 332–339. <https://doi.org/10.1002/nbm.1754> (2012).
- Ronen, I., Ercan, E. & Webb, A. Rapid multi-echo measurement of brain metabolite T-2 values at 7 T using a single-shot spectroscopic Carr-Purcell-Meiboom-Gill sequence and prior information. *NMR Biomed.* **26**, 1291–1298. <https://doi.org/10.1002/nbm.2951> (2013).
- An, L., Li, S. & Shen, J. Simultaneous determination of metabolite concentrations, T1 and T2 relaxation times. *Magn. Reson. Med.* **78**, 2072–2081. <https://doi.org/10.1002/mrm.26612> (2017).
- Li, L., Li, N., An, L. & Shen, J. A novel approach to probing in vivo metabolite relaxation: Linear quantification of spatially modulated magnetization. *Magn. Reson. Med.* **79**, 2491–2499. <https://doi.org/10.1002/mrm.26941> (2018).
- Frahm, J. *et al.* Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. *Magn. Reson. Med.* **11**, 47–63. <https://doi.org/10.1002/mrm.1910110105> (1989).
- Ongur, D. *et al.* T(2) relaxation time abnormalities in bipolar disorder and schizophrenia. *Magn. Reson. Med.* **63**, 1–8. <https://doi.org/10.1002/mrm.22148> (2010).
- Bracken, B. K., Rouse, E. D., Renshaw, P. F. & Olson, D. P. T-2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia. *Psychiatry Res. Neuroimaging* **213**, 142–153. <https://doi.org/10.1016/j.pscyc.2013.03.005> (2013).
- Kowalewski, J. & Maler, L. *Nuclear Spin Relaxation in Liquids: Theory, Experiments and Applications* 2nd edn. (CRC Press, 2019).
- Kuan, E., Chen, X., Du, F. & Ongur, D. N-acetylaspartate concentration in psychotic disorders: T2-relaxation effects. *Schizophr. Res.* **232**, 42–44. <https://doi.org/10.1016/j.schres.2021.04.012> (2021).
- Choi, C. H. *et al.* Improvement of resolution for brain coupled metabolites by optimized H-1 MRS at 7 T. *NMR Biomed.* **23**, 1044–1052. <https://doi.org/10.1002/nbm.1529> (2010).
- Najac, C., Boer, V. O., Kan, H. E., Webb, A. G. & Ronen, I. Improved detection limits of J-coupled neurometabolites in the human brain at 7 T with a J-refocused sLASER sequence. *NMR Biomed.* <https://doi.org/10.1002/nbm.4801> (2022).
- Landheer, K., Gajdosik, M., Treacy, M. & Juchem, C. Concentration and effective T(2) relaxation times of macromolecules at 3T. *Magn. Reson. Med.* **84**, 2327–2337. <https://doi.org/10.1002/mrm.28282> (2020).
- Brereton, I. M., Galloway, G. J., Rose, S. E. & Doddrell, D. M. Localized two-dimensional shift correlated spectroscopy in humans at 2 Tesla. *Magn. Reson. Med.* **32**, 251–257. <https://doi.org/10.1002/mrm.1910320216> (1994).
- Dreher, W. & Leibfritz, D. On the use of two-dimensional-J NMR measurements for in vivo proton MRS: Measurement of homonuclear decoupled spectra without the need for short echo times. *Magn. Reson. Med.* **34**, 331–337. <https://doi.org/10.1002/mrm.1910340309> (1995).
- Ryner, L. N., Sorenson, J. A. & Thomas, M. A. Localized 2D J-resolved ^1H MR spectroscopy: Strong coupling effects in vitro and in vivo. *Magn. Reson. Imaging* **13**, 853–869. [https://doi.org/10.1016/0730-725x\(95\)00031-b](https://doi.org/10.1016/0730-725x(95)00031-b) (1995).
- Kreis, R. & Boesch, C. Spatially localized, one- and two-dimensional NMR spectroscopy and in vivo application to human muscle. *J. Magn. Reson. B* **113**, 103–118. <https://doi.org/10.1006/jmrb.1996.0163> (1996).
- Thomas, M. A. *et al.* Localized two-dimensional shift correlated MR spectroscopy of human brain. *Magn. Reson. Med.* **46**, 58–67. <https://doi.org/10.1002/mrm.1160> (2001).

38. Bax, A. & Freeman, R. Investigation of complex networks of spin-spin coupling by two-dimensional NMR. *J. Magn. Reson.* **44**, 542–561. [https://doi.org/10.1016/0022-2364\(81\)90287-0](https://doi.org/10.1016/0022-2364(81)90287-0) (1981).
39. Girvin, M. E. Increased sensitivity of cosy spectra by use of constant-time T(1) periods (Ct Cosy). *J. Magn. Reson. Ser. A* **108**, 99–102. <https://doi.org/10.1006/jmra.1994.1095> (1994).
40. Dreher, W. & Leibfritz, D. Detection of homonuclear decoupled in vivo proton NMR spectra using constant time chemical shift encoding: CT-PRESS. *Magn. Reson. Imaging* **17**, 141–150. [https://doi.org/10.1016/S0730-725x\(98\)00156-8](https://doi.org/10.1016/S0730-725x(98)00156-8) (1999).
41. Mayer, D., Zahr, N. M., Sullivan, E. V. & Pfefferbaum, A. In vivo metabolite differences between the basal ganglia and cerebellum of the rat brain detected with proton MRS at 3T. *Psychiatry Res. Neuroimaging* **154**, 267–273. <https://doi.org/10.1016/j.pscychres.2006.11.005> (2007).
42. Zahr, N. M. *et al.* In vivo glutamate measured with magnetic resonance spectroscopy: Behavioral correlates in aging. *Neurobiol. Aging* **34**, 1265–1276. <https://doi.org/10.1016/j.neurobiolaging.2012.09.014> (2013).
43. Schulte, R. F. & Boesiger, P. ProFit: Two-dimensional prior-knowledge fitting of J-resolved spectra. *NMR Biomed.* **19**, 255–263. <https://doi.org/10.1002/nbm.1026> (2006).
44. Fuchs, A., Boesiger, P., Schulte, R. F. & Henning, A. ProFit revisited. *Magn. Reson. Med.* **71**, 458–468. <https://doi.org/10.1002/mrm.24703> (2014).
45. Wyss, P. O. *et al.* In vivo estimation of transverse relaxation time constant (T(2)) of 17 human brain metabolites at 3T. *Magn. Reson. Med.* **80**, 452–461. <https://doi.org/10.1002/mrm.27067> (2018).
46. Hurd, R. *et al.* Measurement of brain glutamate using TE-averaged PRESS at 3T. *Magn. Reson. Med.* **51**, 435–440. <https://doi.org/10.1002/mrm.20007> (2004).
47. Zhang, Y. & Shen, J. Simultaneous quantification of glutamate and glutamine by J-modulated spectroscopy at 3 Tesla. *Magn. Reson. Med.* **76**, 725–732. <https://doi.org/10.1002/mrm.25922> (2016).
48. Zhang, Y., An, L. & Shen, J. Fast computation of full density matrix of multispin systems for spatially localized in vivo magnetic resonance spectroscopy. *Med. Phys.* **44**, 4169–4178. <https://doi.org/10.1002/mp.12375> (2017).
49. An, L., Araneta, M. F., Johnson, C. & Shen, J. Effects of carrier frequency mismatch on frequency-selective spectral editing. *Magn. Reson. Mater. Phys. Biol. Med.* **32**, 237–246. <https://doi.org/10.1007/s10334-018-0717-5> (2019).
50. An, L. *et al.* Roles of strong scalar couplings in maximizing glutamate, glutamine and glutathione pseudo singlets at 7 tesla. *Front. Phys.* <https://doi.org/10.3389/fphy.2022.927162> (2022).
51. Hong, S., An, L. & Shen, J. Monte Carlo study of metabolite correlations originating from spectral overlap. *J. Magn. Reson.* **341**, 107257. <https://doi.org/10.1016/j.jmr.2022.107257> (2022).
52. Hong, S. & Shen, J. Neurochemical correlations in short echo time proton magnetic resonance spectroscopy. *NMR Biomed.* **36**, e4910. <https://doi.org/10.1002/nbm.4910> (2023).
53. Ganji, S. K. *et al.* T2 measurement of J-coupled metabolites in the human brain at 3T. *NMR Biomed.* **25**, 523–529. <https://doi.org/10.1002/nbm.1767> (2012).
54. Bottomley, P. A. Selective volume method for performing localized NMR spectroscopy. *Magn. Reson. Imaging* [https://doi.org/10.1016/0730-725X\(85\)90032-3](https://doi.org/10.1016/0730-725X(85)90032-3) (1984).
55. Sorensen, O. W., Eich, G. W., Levitt, M. H., Bodenhausen, G. & Ernst, R. R. Product operator-formalism for the description of NMR pulse experiments. *Prog. Nucl. Magn. Reson. Spectrosc.* **16**, 163–192 (1983).
56. Vandeven, F. J. M. & Hilbers, C. W. A simple formalism for the description of multiple-pulse experiments—Application to a weakly coupled 2-spin ($i = 1/2$) system. *J. Magn. Reson.* **54**, 512–520. [https://doi.org/10.1016/0022-2364\(83\)90331-1](https://doi.org/10.1016/0022-2364(83)90331-1) (1983).
57. Packer, K. J. & Wright, K. M. The use of single-spin operator basis-sets in the NMR-spectroscopy of scalar-coupled spin systems. *Mol. Phys.* **50**, 797–813. <https://doi.org/10.1080/00268978300102691> (1983).
58. Emsley, L. & Bodenhausen, G. Phase-shifts induced by transient Bloch-Siegert effects in NMR. *Chem. Phys. Lett.* **168**, 297–303. [https://doi.org/10.1016/0009-2614\(90\)85614-1](https://doi.org/10.1016/0009-2614(90)85614-1) (1990).
59. Frahm, J., Merboldt, K. D. & Hanicke, W. Localized proton spectroscopy using stimulated echoes. *J. Magn. Reson.* **72**, 502–508. [https://doi.org/10.1016/0022-2364\(87\)90154-5](https://doi.org/10.1016/0022-2364(87)90154-5) (1987).
60. An, L., van der Veen, J. W., Li, S. Z., Thomasson, D. M. & Shen, J. Combination of multichannel single-voxel MRS signals using generalized least squares. *J. Magn. Reson. Imaging* **37**, 1445–1450. <https://doi.org/10.1002/jmri.23941> (2013).

Acknowledgements

We thank Christopher S. Johnson, MS, Maria Ferraris Araneta, CRNP, Tara Turon, CRNP, and Inna Loutaev, DNP & CRNP, for generous and valuable help.

Author contributions

J.S. and L.A. conceived the technique and prepared the manuscript. L.A. developed the technology and performed the experiments.

Funding

Open Access funding provided by the National Institutes of Health (NIH). This study (NCT01266577) was supported by the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH, ZIAMH002803).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-39375-0>.

Correspondence and requests for materials should be addressed to L.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023